NZ732235A - Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form - Google Patents

Abstract

The specification and claims are directed to the composition known in the art as Epanova®. Epanova® comprises eicosapentaenoic acid (“EPA”), in a weight percent amount of 50% to 60%; docosahexaenoic acid (“DHA”) in a weight percent amount of 17% to 23%; and docosapentaenoic acid (n-3) (“DPA”) (clupanodonic acid) in a weight percent amount of 1% to 8%; and wherein at least 90% by weight of the polyunsaturated acid in the composition is present in the free acid form. In a preferred embodiment Epanova® is to be presented in the form of capsule for oral administration of a Type A porcine soft gelatin capsule coated with poly(acrylatemethylmethacrylate) copolymer (Eudragit NE 30-D), and containing one gram of a PUFA composition in which the polyunsaturated fatty acids are present in the form of free fatty acids and contains: 0.55% linoleic acid; 0.15% gamma-linolenic acid; 0.39% alpha-linolenic acid; 1.70% moroctic acid; 0.10% eicosadienoic acid; 0.35% dihomo-gamma-linolenic acid; 2.43% arachidonic acid; 0.15% eicosatrienoic acid; 2.18% eicosatetraenoic acid; 57.25% eicosapentaenoic acid (EPA); 2.79% heneicosapentaenoic acid; 0.83% docosapentaenoic acid; 6.23% docosapentaenoic acid (DPA); and 19.58% docosahexaenoic acid (DHA). Also disclosed is Epanova® for use in the treatment of severe hypertriglyceridemia, wherein the treatment comprises: orally administering the composition to a patient having pre-treatment serum or plasma triglyceride levels ≥500 mg/dL, in an amount and for a duration effective to reduce serum or plasma triglycerides below pre-treatment levels.